View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Assa Abloy AB: 1 director

A director at Assa Abloy AB bought 5,000 shares at 298.530SEK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

HII Declares Quarterly Dividend

HII Declares Quarterly Dividend NEWPORT NEWS, Va., May 01, 2024 (GLOBE NEWSWIRE) -- HII (NYSE: HII) announced today that its Board of Directors has declared a quarterly cash dividend of $1.30 per share, payable on June 14, 2024, to shareholders of record as of the close of business on May 31, 2024. About HII HII is a global, all-domain defense provider. HII’s mission is to deliver the world’s most powerful ships and all-domain solutions in service of the nation, creating the advantage for our customers to protect peace and freedom around the world. As the nation’s largest military ship...

Eyeonid Group AB: 1 director

A director at Eyeonid Group AB bought 200,000 shares at 10.000SEK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

Jiangsu Jinling Sports Equipment Co Ltd: 1 director

A director at Jiangsu Jinling Sports Equipment Co Ltd bought 200,000 shares at 13.940CNY and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...

 PRESS RELEASE

Freddie Mac Announces First Quarter 2024 Financial Results

Freddie Mac Announces First Quarter 2024 Financial Results MCLEAN, Va., May 01, 2024 (GLOBE NEWSWIRE) -- Freddie Mac (OTCQB: FMCC) today reported its First Quarter 2024 financial results and filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission. The company’s Form 10-Q and earnings press release, along with the First Quarter 2024 financial results supplement are available now on the of the company’s website. The company will hold a call at 9 a.m. Eastern Time (ET) today, May 1, 2024, to share its results with the media. The call will be concurrentl...

Andy Hanson
  • Andy Hanson

Audio Note: Topps Group - Initiation: Market leader trading at cyclica...

In this audio note, Zeus’ Andy Hanson summarises the investment case for Topps Group. Topps Group is the UK’s largest specialist supplier and distributor of tiles and associated products to the UK’s domestic and commercial markets. Listen to the audio note below, and read the full research here.

Banque Heritage SA: Update following affirmation of ratings

Our credit view of Banque Heritage reflecting its sound asset quality, strong capitalisation, and materially improved profitability, which is balanced by concentration and governance risks.

 PRESS RELEASE

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Op...

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives Acquire cell therapy manufacturing facility with clinical and commercial capabilitiesFurther ExacTcell platform for additional clinical trials based on successful completion of POCHighlight full year financial results and clarify key financial items WARREN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- (“Tevogen” or “Tevogen Bio”) (Nasdaq: ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virolo...

 PRESS RELEASE

electroCore to Announce First Quarter March 31, 2024 Financial Results...

electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024 ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of the market on Wednesday, May 8, 2024. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions. Wednesday, May 8, 4:30 PM EDTDomestic: 877-407-8835International: Conferen...

 PRESS RELEASE

Dalata Hotel Group PLC: TVR-Total Voting Rights

Dalata Hotel Group PLC (DAL,DHG) Dalata Hotel Group PLC: TVR-Total Voting Rights 01-May-2024 / 12:58 GMT/BST   Total Voting Rights   ISE: DHG   LSE: DAL     In conformity with Regulation 20 of the Transparency (Directive 2004/109/EC) Regulations 2007, Dalata Hotel Group plc announces that: As of 1 May 2024, Dalata Hotel Group plc’s share capital consists of 224,430,160 Ordinary Shares of nominal value €0.01 each.  Dalata Hotel Group plc does not hold any Ordinary Shares in treasury.  Therefore, the total number of voting rights in Dalata Hotel Group plc is 224,430,160. The ...

 PRESS RELEASE

Radiation-Tolerant PolarFire® SoC FPGAs Offer Low Power, Zero Configur...

Radiation-Tolerant PolarFire® SoC FPGAs Offer Low Power, Zero Configuration Upsets, RISC-V Architecture for Space Applications Along with Microchip’s Mi-V ecosystem, new device family helps system designers to lower power, size and weight and speed time to market CHANDLER, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Developers of spacecraft electronics utilize radiation-tolerant (RT) field programmable gate arrays (FPGAs) to ensure high performance, reliability, power-efficiency and the best-in-class security for emerging space domain threats. To take it a step further and help provide fast...

 PRESS RELEASE

Recursion to Participate in Upcoming Investor Conferences

Recursion to Participate in Upcoming Investor Conferences SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences: Bank of America Securities Healthcare Conference – May 14-16, 202452nd Annual JP Morgan Global Technology Conference – May 20-22, 2024 About Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recur...

 PRESS RELEASE

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO. Rachelle Jacques will step down as Akari’s Chief Executive Officer effective today. Melissa Bradford-Klug will step down as Akari’s Chief Operating Officer effective today. In connection with Ms. J...

 PRESS RELEASE

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan...

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity Prioritization of Peak’s ADC cancer therapeutic platform technology and Akari’s PAS-nomacopan for Geographic Atrophy, a disabling ophthalmic diseaseAkari Therapeutics announces leadership changes in separate Akari press release BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint portfolio prioritization review pursuant to which the combined entity...

 PRESS RELEASE

Locafy Reports Fiscal Third Quarter 2024 Results

Locafy Reports Fiscal Third Quarter 2024 Results Company Striving Towards Near-Term Profitability Following Go-to-Market Approach Revamp and Cost Reduction Initiatives New Pay-Per-Click SEO Pricing Model Gaining Strong Traction in Multiple Market Sectors Streamlined Operations Results in Record Quarterly Gross Margin of 83.6% PERTH, Australia, May 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized software-as-a-service technology company specializing in “entity-based” search engine optimization (SEO), today reported financial result...

 PRESS RELEASE

Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree...

Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree®The percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled in just two years (2020-2022)1Although symptoms are present in childhood, a significant portion of women with ADHD don’t receive a diagnosis until they are adults2 ROCKVILLE, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Actress, author, podcaster, and mother of two, Busy Philipps is teaming up with Supernus Pharmaceuticals ...

 PRESS RELEASE

Conduent Reports First Quarter 2024 Financial Results

Conduent Reports First Quarter 2024 Financial Results Key Q1 2024 Highlights Revenue: $921MPre-tax Income: $127MAdj. EBITDA Margin(1): 7.5%New business signings ACV(2): $99MNet ARR Activity Metric(2) (TTM): $17M FLORHAM PARK, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Conduent (NASDAQ: CNDT), a global technology-led business process solutions and services company, today announced its first quarter 2024 financial results. Cliff Skelton, Conduent President and Chief Executive Officer stated, “Q1 2024 is a continued reflection of progress in our portfolio performance overlaid by t...

 PRESS RELEASE

Carpenter Technology Reports Third Quarter Fiscal Year 2024 Results

Carpenter Technology Reports Third Quarter Fiscal Year 2024 Results Exceeded Third Quarter Operating Income GuidanceIncreasing Fourth Quarter Operating Income OutlookGenerated Positive Free Cash Flow PHILADELPHIA, May 01, 2024 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) (the “Company”) today announced financial results for the fiscal third quarter ended March 31, 2024. For the quarter, the Company reported operating income of $75.9 million, and earnings per diluted share of $0.12. Excluding noncash special items discussed below, adjusted operating income was $90....

 PRESS RELEASE

Lightbridge to Hold Business Update & First Quarter 2024 Earnings Conf...

Lightbridge to Hold Business Update & First Quarter 2024 Earnings Conference Call on Friday, May 10th at 11 a.m. ET RESTON, Va., May 01, 2024 (GLOBE NEWSWIRE) -- Lightbridge Corporation (“Lightbridge”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, will announce its financial results for the first quarter of fiscal year 2024 on Thursday, May 9th after the market closes. Lightbridge will host a conference call on Friday, May 10, at 11:00 AM ET with the investment community to discuss the Company’s financial results and provide an update on its fuel development activities. ...

 PRESS RELEASE

Denali Therapeutics Announces Completion of Enrollment for Regimen G E...

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G o...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch